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To the editor: Saran et al.1 reported in their recent study that
longer treatment and slower ultrafiltration in hemodialysis
resulted in reduced mortality. However, their study could not
rule out the interference of the awareness of treatment time
(TT). In Japan there was stronger correlation between TT and
urea kinetics (Kt/V) than that in Europe or the US (0.14
versus 0.03 or 0.01). That is presumably because TT in Japan
depends more remarkably on net total filtration volume
whereas TT in Europe and the US depends on Kt/V. Japanese
are sufficiently small for body size achievable target Kt/V
within that of ultrafiltration rate (UFR).
This study concluded that the cardiopulmonary mortality
is less influenced by the effect of longer TT and lower UFR
than that of all-cause mortality. We are concerning if there
were careful considerations for the following points. We
usually prescribe TT to achieve target Kt/V and/or to achieve
target dry weight using safer maximal UFR. Sometimes,
lower maximal UFR is obligatory required because of low
cardiac function and low blood pressure. We wonder if this
report included certain number of such cases. If so, it will
potentially reduce the power of lower UFR to detect
cardiopulmonary risk. Admittedly, in a previous report, low
systolic blood pressure inducing lower maximal UFR
associate with high risk for mortality.2 These aspects are
not clearly discussed in this article.
UFR (ml/h/kg) and Kt/V is full dependent factor of TT,
which is overlooked in this study. It should have been more
confident if the UFR (ml/h/kg) is changed to total ultra-
filtration volume (ml/session/kg) and Kt/V to time limited
Kt/V (e.g. TT 210 min only). TT must be carefully handled in
multivariate analysis about UFR.
1. Saran R, Bragg-Gresham JL, Port FK et al. Longer treatment time and
slower ultrafiltration in hemodialysis: associations with reduced mortality
in the DOPPS. Kidney Int 2006; 69: 1222–1228.
2. Port FK, Hulbert-Shearon TE, Young EW et al. Predialysis blood pressure
and mortality risk in a national sample of maintenance hemodialysis
patients. Am J Kidney Dis 1999; 33: 507–517.
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Response to ‘Longer treatment
time and slower ultrafiltration in
hemodialysis: Associations with
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and Practice Patterns Study’
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We are grateful to Dr Okamoto et al.1 for providing
insightful comments in response to our published paper
dealing with the issues of treatment time (TT) and
ultrafiltration rate (UFR) in the Dialysis Outcomes and
Practice Patterns Study.2 We wish to respond to the three
main points they make. (I) They speculate that the reason
for the relatively strong correlation observed between TT
and Kt/V in Japan is because TT in Japan is decided based
on total ultrafiltration volume, whereas in Europe and the
US, TT is more dependent on target Kt/V. They also make
the point that it is perhaps easier to achieve target Kt/V in
Japan owing to the relatively smaller body size of the
Japanese patients (we agree with this statement). We have
previously observed in the Dialysis Outcomes and Practice
Patterns Study that interdialytic weight gains are, on
average, relatively higher in Japan.3 It may well be that TT
in Japan is usually at or above 4 h because they target the
ultrafiltration volume over a longer time owing to the
belief that longer TT is useful in the delivery of
hemodialysis, a practice pattern that reflects achievement
of dialysis adequacy by prolonging time (as we discuss in
the paper) rather than other measures such as higher blood
flow rate or utilization of larger dialyzers which are more
likely to be used in the US. (II) It is quite possible that low
UFR is generally applied when patient’s blood pressure is
low predialysis, or for the prevention of intradialytic
hypotension. Even if there is such confounding as Dr
Okinamoto et al. suggest, the results are independent of
the multiple co-morbidities that were adjusted for in our
analyses, and suggest that low UFR may actually be pro-
tective for all-cause mortality. We agree that low UFR may
be more weakly associated with reduced cardiovascular
mortality because of the fact that it is confounded by low
blood pressure, which itself is a predictor of higher
mortality in dialysis patients. However, this hypothesis
would need to be tested formally. (III) We recognized that
both UFR (ml/min/kg) and Kt/V have ‘T’ in them.
However, the Cox proportional hazards models have both
variables simultaneously and TT. Despite potential colli-
nearity, the variables are independently associated with
outcomes. Furthermore, we reported an interaction
between Kt/V and T, such that for any Kt/V a longer time
was independently protective. This interaction directly
addresses the ‘time-limited Kt/V’ issue, which is raised in
the letter. Overall, the points made by Drs Okamoto,
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Kobayashi and Noiri do not argue against the validity of
our reported significant correlations of TT and UFR with
mortality risk, but suggest that our report may offer an
underestimate of the true magnitude of potential benefits
from longer TT and slower UFR.
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Calculation of glomerular
filtration rate using serum cystatin
C in kidney transplant recipients
Kidney International (2006) 70, 1878. doi:10.1038/sj.ki.5001843
To the Editor: Recently, Rule et al.1 demonstrated a 19%
higher glomerular filtration rate at the same cystatin C (Cys
C) level among patients after renal transplantation in
comparison to patients with native kidney disease. Thus, a
new Cys C-based formula (glomerular filtration rate-
76.6Cys C1.16) was suggested for transplant recipients
(TX formula). We analyzed the diagnostic performance of the
new TX formula in comparison to two other Cys C formulae
(Larsson and Hoek2,3) which are based on the same Cys C
assay in a cohort of 108 patients after renal transplantation.
Glomerular filtration rate was determined by 99mtechnetium-
labeled diethylenetriamine penta acetate clearance. Results
are given in Table 1.
Although the Larsson and Hoek formulae were not
derived from a transplanted cohort, their diagnostic perfor-
mances are at least comparable to the TX equation. Thus, two
conclusions can be drawn from this analysis: (1) calibration
differences between the different laboratories may counteract
the putative advantages of the new TX formula, (2) this
rather disappointing performance of the TX equation may
also be due to possible confounders like steroid dosing which
may crucially affect Cys C levels.4
To enhance the performance of future Cys C-based
glomerular filtration rate equations such cofactors should
be taken into account.
1. Rule AD, Bergstralh EJ, Slezak JM et al. Glomerular filtration rate estimated
by cystatin C among different clinical presentations. Kidney Int 2006; 69:
399–405.
2. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular
filtration rate expressed in ml/min from plasma cystatin C values in mg/l.
Scand J Clin Lab Invest 2004; 64: 25–30.
3. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C,
plasma creatinine and the Cockcroft and Gault formula for the
estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18:
2024–2031.
4. Poge U, Gerhardt TM, Stoffel-Wagner B et al. {beta} Trace protein is an
alternative marker for glomerular filtration rate in renal transplantation
patients. Clin Chem 2005; 51: 1531–1533.
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We appreciate the work by Po¨ge et al.1 to test the
performance of our transplant equation.2 Remarkably,
the equation performed well with little bias (1.6 ml/min/
1.73 m2) in their transplant recipients. There was also little
bias with the Larsson3 and Hoek4 equations, which were
not specifically developed using transplant recipients.
However, we note that our finding of a higher glomerular
filtration rate (GFR) in transplant recipients (kidney or
other organ) compared to native chronic kidney disease
(CKD) patients is consistent with reports by other
investigators.5,6 In these centers, one equation cannot
accurately estimate GFR in both transplant and native
CKD patients unless it includes variables for transplant
Table 1 | Comparison of performance of the different cystatin C based formulae
Mean estimates
(ml/min/1.73 m2)
Range
(ml/min/1.73 m2)
Correlation
coefficient
Bias
(ml/min/1.73 m2)
Median
difference
(ml/min/1.73 m2)
Precision
(ml/min/
1.73 m2)
Accuracy within
30% (95% CI) 50% (95% CI)
DTPA 39.5 11.8–82.9
Larsson 36.3 7.78–104 0.859 3.20 4.78 9.59 77.1 95.4
Hoek 38.9 8.72–97.4 0.865 0.58 1.50 8.64 77.1 97.2
Rule 37.9 9.30–101 0.862 1.60 2.78 9.15 78.0 89.0
CI, confidence interval; DTPA, diethylenetriamine penta acetate.
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